BGI, University of Manchester Launch Synthetic Biology Collaboration

05:33 EST 10 Nov 2017 | Genetic Engineering News

BGI and the University of Manchester have launched a five-year collaboration focused on synthetic biology and metabolic engineering. The partnership, whose value was not disclosed, will focus on synthetic biology and metabolic engineering of natural products, BGI said, with the goals of promoting academic research, education and industrialization. The collaboration will draw upon the work of Yizhi (Patrick) Cai, Ph.D., chair in synthetic genomics at the University of Manchester, whose lab is involved with the synthetic yeast genome consortium (Sc2.0), which aims to re-design and synthesize a 12 Mb designer yeast genome de novo. Among synthetic genomics projects his lab is working on, according to his lab website, are the Induced Evolution of Synthetic Yeast genomes (IESY) project, which applies the Synthetic Chromosome Rearrangement and Modification by LoxP-mediated evolution (SCRaMbLE) system to generate high-fitness yeast cells with synthetic chromosomes under specific conditions. Dr. Cai’s lab ...

Original Article: BGI, University of Manchester Launch Synthetic Biology Collaboration


More From BioPortfolio on "BGI, University of Manchester Launch Synthetic Biology Collaboration"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...